Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.

Ruben A MesaStacie HudgensLysbeth FlodenClaire N HarrisonJeanne PalmerVikas GuptaDonal P McLornanMary F McMullinJean-Jaques KiladjianLynda FoltzUwe PlatzbeckerM Laura FoxAdam J MeadDavid M RossStephen T OhAndrew PerkinsMichael F LeahySamineh DeheshiRafe DonahueBarbara J KlenckeSrdan Verstovsek

Published in: Cancer medicine (2023)

These findings suggest that momelotinib provides clinically relevant symptom benefits in the JAK inhibitor-naïve and JAK inhibitor-exposed settings.

Keyphrases

phase iii
open label
clinical trial
phase ii
placebo controlled
randomized controlled trial
patient reported